See today's BioWorld Science
To read the full story, subscribe or sign in.
Gastrointestinal

Neurenati’s NEU-001 awarded orphan drug designation for Hirschsprung disease

March 5, 2025
Neurenati Therapeutics Inc.’s NEU-001 has been awarded U.S. orphan drug and rare pediatric disease designations by the FDA for the treatment of Hirschsprung disease.
BioWorld Science Regulatory Gastrointestinal Genetic/congenital FDA Orphan drug